Tags

Type your tag names separated by a space and hit enter

Evaluation of the clinical utility of urocortin 1 in systolic heart failure.
Kardiol Pol. 2014; 72(5):452-8.KP

Abstract

BACKGROUND

Urocortin 1 (UCN1) has cardiostimulatory, vasodilatory, diuretic and natriuretic effects, and its expression increases in heart failure (HF).

AIM

To determine UCN1 levels in patients with HF, to evaluate UCN1's relationship with various clinical parameters, and to assess UCN1 as a diagnostic marker in HF, compared to pro-B-type natriuretic peptide (pro-BNP).

METHODS

We investigated serum levels of UCN1 and pro-BNP in 90 consecutive patients with systolic HF (left ventricular ejection fraction [LVEF] ≤ 45%) and 90 healthy controls. Serum UCN1 and pro-BNP levels were measured using the ELISA method. Transthoracic echocardiography was performed to determine LVEF and pulmonary artery systolic pressure (PASP). Glomerular filtration rate (GFR) was estimated using the Cockcroft-Gault formula.

RESULTS

UCN1 level was higher in HF patients (391.5 [357.0-482.0] pg/mL, p < 0.001). UCN1 was positively related with NYHA class (r = 0.89, p < 0.001), and PASP (r = 0.39, p < 0.001); and negatively related with LVEF (r = -0.46, p < 0.001), and GFR (r = -0.21, p = 0.046). A significant positive correlation was found between pro-BNP and UCN1 levels (p < 0.001, r = 0.96). Receiver operating characteristic (ROC) curves yielded an area under the curve (AUC) of 0.99 (95% CI 0.98-1.00,p < 0.001) for UCN1 and 1.00 (p < 0.001) for pro-BNP in the diagnosis of HF.

CONCLUSIONS

UCN1 increases with worsening HF and left ventricular dysfunction. It may be used as a diagnostic biomarker in systolic HF, but the incremental value of measuring UCN1 in patients tested for pro-BNP is questionable.

Authors+Show Affiliations

No affiliation info availableNo affiliation info availableIstanbul University, Cerrahpasa Medical Faculty, Department of Cardiology. altugcakmak@hotmail.com.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

24408067

Citation

Yildirim, Erkan, et al. "Evaluation of the Clinical Utility of Urocortin 1 in Systolic Heart Failure." Kardiologia Polska, vol. 72, no. 5, 2014, pp. 452-8.
Yildirim E, Keles I, Cakmak HA, et al. Evaluation of the clinical utility of urocortin 1 in systolic heart failure. Kardiol Pol. 2014;72(5):452-8.
Yildirim, E., Keles, I., Cakmak, H. A., Cosansu, K., Can, G., & Ikitimur, B. (2014). Evaluation of the clinical utility of urocortin 1 in systolic heart failure. Kardiologia Polska, 72(5), 452-8. https://doi.org/10.5603/KP.a2013.0353
Yildirim E, et al. Evaluation of the Clinical Utility of Urocortin 1 in Systolic Heart Failure. Kardiol Pol. 2014;72(5):452-8. PubMed PMID: 24408067.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evaluation of the clinical utility of urocortin 1 in systolic heart failure. AU - Yildirim,Erkan, AU - Keles,Ibrahim, AU - Cakmak,Huseyin Altug, AU - Cosansu,Kahraman, AU - Can,Gunay, AU - Ikitimur,Baris, Y1 - 2014/01/10/ PY - 2013/09/11/received PY - 2013/12/09/accepted PY - 2013/11/04/revised PY - 2014/1/11/entrez PY - 2014/1/11/pubmed PY - 2016/12/15/medline SP - 452 EP - 8 JF - Kardiologia polska JO - Kardiol Pol VL - 72 IS - 5 N2 - BACKGROUND: Urocortin 1 (UCN1) has cardiostimulatory, vasodilatory, diuretic and natriuretic effects, and its expression increases in heart failure (HF). AIM: To determine UCN1 levels in patients with HF, to evaluate UCN1's relationship with various clinical parameters, and to assess UCN1 as a diagnostic marker in HF, compared to pro-B-type natriuretic peptide (pro-BNP). METHODS: We investigated serum levels of UCN1 and pro-BNP in 90 consecutive patients with systolic HF (left ventricular ejection fraction [LVEF] ≤ 45%) and 90 healthy controls. Serum UCN1 and pro-BNP levels were measured using the ELISA method. Transthoracic echocardiography was performed to determine LVEF and pulmonary artery systolic pressure (PASP). Glomerular filtration rate (GFR) was estimated using the Cockcroft-Gault formula. RESULTS: UCN1 level was higher in HF patients (391.5 [357.0-482.0] pg/mL, p < 0.001). UCN1 was positively related with NYHA class (r = 0.89, p < 0.001), and PASP (r = 0.39, p < 0.001); and negatively related with LVEF (r = -0.46, p < 0.001), and GFR (r = -0.21, p = 0.046). A significant positive correlation was found between pro-BNP and UCN1 levels (p < 0.001, r = 0.96). Receiver operating characteristic (ROC) curves yielded an area under the curve (AUC) of 0.99 (95% CI 0.98-1.00,p < 0.001) for UCN1 and 1.00 (p < 0.001) for pro-BNP in the diagnosis of HF. CONCLUSIONS: UCN1 increases with worsening HF and left ventricular dysfunction. It may be used as a diagnostic biomarker in systolic HF, but the incremental value of measuring UCN1 in patients tested for pro-BNP is questionable. SN - 1897-4279 UR - https://www.unboundmedicine.com/medline/citation/24408067/Evaluation_of_the_clinical_utility_of_urocortin_1_in_systolic_heart_failure_ L2 - https://doi.org/10.5603/KP.a2013.0353 DB - PRIME DP - Unbound Medicine ER -